Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area

Young Joo Jin, Jin Woo Lee, Jung II Lee, Sang Hoon Park, Choong Kee Park, Young Seok Kim, Sook Hyang Jeong, Yun Soo Kim, Ju Hyun Kim, Seong Gyu Hwang, Kyu Sung Rim, Hyung Joo Yim, Jae Youn Cheong, Sung Won Cho, June Sung Lee, Young Min Park, Jeong Won Jang, Chun Kyon Lee, Joo Hyun Sohn, Jin Mo YangSeungbong Han

Research output: Contribution to journalArticle

Abstract

Background/Aim: Two recent Italian studies suggested that Pegylated-interferon (PEG-IFN) alfa-2a achieves a higher sustained virological response (SVR) rate than PEG-IFN alfa-2b. We intended to compare the efficacy and safety of PEG-IFN alfa-2a with those of PEG-IFN alfa-2b in Korean patients with chronic hepatitis C virus (HCV). Methods: This retrospective, multi-center trial was conducted on 661 treatment-naïve chronic HCV patients. Patients received PEG-IFN alfa-2a (180 μg/week; n=402) or PEG-IFN alfa-2b (1.5 μg/kg/week; n=259) with ribavirin (800-1200 mg/day) for 24 or 48 weeks according to HCV genotypes. Results: Early virological response (EVR), end-of-treatment response (ETR), and SVR rates were not significantly different between two PEG-IFN groups both in patients with HCV genotype 1 (all P-values >0.05) and 2/3 (all P-values >0.05). SVR rates were not different between two groups in each categorized baseline characteristics: age (years) (≤ 50 and >50), HCV viral load (IU/mL) (≤ 7×105 and >7×105), and hepatic fibrosis (F0-2 and F3-4) (all P-values>0.05). In additional analysis for 480 patients who sufficiently complied with treatment doses and duration (80/80/80 rule) and propensity-score matched analysis, SVR rates were not different between two groups both in patients with HCV genotype 1 and 2/3 (all P-values>0.05). Adverse event rates were similar between two groups. Conclusions: Unlike the Western data, efficacy and safety of PEG-IFN alfa-2a were similar to those of PEG-IFN alfa-2b in chronically HCV-infected Korean patients regardless of age, HCV viral load, and hepatic fibrosis.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalJournal of Antivirals and Antiretrovirals
Volume4
Issue number4
DOIs
Publication statusPublished - 2012

Keywords

  • Chronic hepatitis C
  • Pegylated interferon alfa-2a
  • Pegylated interferon alfa-2b
  • Ribavirin
  • Sustained virological response

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Fingerprint Dive into the research topics of 'Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area'. Together they form a unique fingerprint.

  • Cite this

    Jin, Y. J., Lee, J. W., Lee, J. II., Park, S. H., Park, C. K., Kim, Y. S., Jeong, S. H., Kim, Y. S., Kim, J. H., Hwang, S. G., Rim, K. S., Yim, H. J., Cheong, J. Y., Cho, S. W., Lee, J. S., Park, Y. M., Jang, J. W., Lee, C. K., Sohn, J. H., ... Han, S. (2012). Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naive HCV patients in favourable IL28B genotype dominant area. Journal of Antivirals and Antiretrovirals, 4(4), 80-87. https://doi.org/10.4172/jaa.1000050